Risk of scar in the comparison of age-related macular degeneration treatments trials.
暂无分享,去创建一个
Jiayan Huang | G. Ying | M. Maguire | S. Fine | Daniel F. Martin | C. Toth | J. Grunwald | E. Daniel | G. Jaffe | S. Hagstrom | K. Winter | G. Ying | Ebenezer Daniel
[1] Glenn J Jaffe,et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. , 2013, Ophthalmology.
[2] Sandra S Stinnett,et al. Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. , 2012, Ophthalmology.
[3] R. Tadayoni,et al. CAUSES OF UNSUCCESSFUL RANIBIZUMAB TREATMENT IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION IN CLINICAL SETTINGS , 2012, Retina.
[4] Ebenezer Daniel,et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. , 2012, Ophthalmology.
[5] M. Moschos,et al. LONG-TERM RESULTS OF INTRAVITREAL RANIBIZUMAB, INTRAVITREAL RANIBIZUMAB WITH PHOTODYNAMIC THERAPY, AND INTRAVITREAL TRIAMCINOLONE WITH PHOTODYNAMIC THERAPY FOR THE TREATMENT OF RETINAL ANGIOMATOUS PROLIFERATION , 2012, Retina.
[6] Laura G. Qualls,et al. Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries. , 2012, American journal of ophthalmology-glaucoma.
[7] C. Toth,et al. Reproducibility of Optical Coherence Tomography Image Grading During the Comparisons of Age-Related Macular Degeneration Treatments Trials (CATT) , 2012 .
[8] R. Goldschmeding,et al. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy , 2012, British Journal of Ophthalmology.
[9] R. Zawadzki,et al. TEN-YEAR FOLLOW-UP OF EYES TREATED WITH STEREOTACTIC FRACTIONATED EXTERNAL BEAM RADIATION FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2011, Retina.
[10] D. Roth,et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. , 2011, Ophthalmology.
[11] Glenn J Jaffe,et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.
[12] P. Rosenfeld,et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. , 2011, Ophthalmology.
[13] John C. Hwang,et al. Development of subretinal fibrosis after anti-VEGF treatment in neovascular age-related macular degeneration. , 2011, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.
[14] E. O'Neill,et al. Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro. , 2010, Investigative ophthalmology & visual science.
[15] Yusuke Nakamura,et al. A genome-wide association study identifies four susceptibility loci for keloid in the Japanese population , 2010, Nature Genetics.
[16] W. Spileers,et al. Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery. , 2009, Investigative ophthalmology & visual science.
[17] R. Varma,et al. Postoperative use of bevacizumab as an antifibrotic agent in glaucoma filtration surgery in the rabbit. , 2009, Investigative ophthalmology & visual science.
[18] G. Staurenghi,et al. RETINAL ANGIOMATOUS PROLIFERATION: Natural History and Progression of Visual Loss , 2009, Retina.
[19] P. Presti,et al. Relationships between clinical measures of visual function and anatomic changes associated with bevacizumab treatment for choroidal neovascularization in age-related macular degeneration , 2009, Eye.
[20] V. Bergdall,et al. Regulation of scar formation by vascular endothelial growth factor , 2008, Laboratory Investigation.
[21] J. Vander,et al. Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results , 2008 .
[22] Usha Chakravarthy,et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. , 2008, Ophthalmology.
[23] Peter K Kaiser,et al. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. , 2007, Ophthalmology.
[24] Gerald Liew,et al. Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.
[25] J. Vander. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationBrown DM, for the ANCHOR Study Group (Methodist Hosp, Houston; et al) N Engl J Med 355:1432–1444, 2006§ , 2007 .
[26] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[27] J. V. van Meurs,et al. Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. , 2006, Archives of ophthalmology.
[28] P. Beaumont,et al. Lesion morphology in age-related macular degeneration and its therapeutic significance. , 2006, Archives of ophthalmology.
[29] Peter K. Kaiser,et al. ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006 .
[30] G. Saleh,et al. Does lesion size determine the success rate of photodynamic therapy for age-related macular degeneration? , 2006, Eye.
[31] D. Pauleikhoff,et al. NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Natural History and Treatment Outcomes , 2005, Retina.
[32] C. Kanellitsas,et al. The Age-Related Macular Degeneration Radiotherapy Trial ( AMDRT ) : One Year Results from a Pilot Study , 2004 .
[33] J. Winder,et al. Identification of lesion components that influence visual function in age related macular degeneration , 2003, The British journal of ophthalmology.
[34] M. Humayun,et al. MORPHOMETRIC ANALYSIS OF THE MACULA IN EYES WITH DISCIFORM AGE-RELATED MACULAR DEGENERATION , 2002, Retina.
[35] J W Berger,et al. Age-related macular degeneration. , 2000, The New England journal of medicine.
[36] P. Romano. Association for Research in Vision and Ophthalmology. , 2000, Binocular vision & strabismus quarterly.
[37] G. Soubrane,et al. Natural History of Macular Subretinal Hemorrhage in Age-Related Macular Degeneration , 1999, Ophthalmologica.
[38] M G Maguire,et al. Occult choroidal neovascularization in age-related macular degeneration. A natural history study. , 1997, Archives of ophthalmology.
[39] R. Avery,et al. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. , 1996, Retina.
[40] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[41] W R Green,et al. Age-related Macular Degeneration Histopathologic Studies: The 1992 Lorenz E. Zimmerman Lecture , 1993, Ophthalmology.
[42] R P Murphy,et al. Natural course of poorly defined choroidal neovascularization associated with macular degeneration. , 1988, Archives of ophthalmology.
[43] A. Bird,et al. Senile disciform macular degeneration in the second eye. , 1977, The British journal of ophthalmology.
[44] H. Zauberman,et al. The macular vessels in predisciform and disciform senile macular degeneration. , 1970, American journal of ophthalmology.
[45] C. Walker. Ophthalmology , 1859, Bristol medico-chirurgical journal.